- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Vicarious Surgical plans to submit a de novo filing to the FDA, and Fromm has been appointed as its new CEO.
4 reports, 3 independent
Updated Aug 14
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Vicarious Surgical plans to submit a de novo filing to the FDA, and Fromm has been appointed as its new CEO.
Who's involved
What this event is mainly aboutFDAFromm
How it developed
Newest first. Tap a step to see who reported it.Vicarious Surgical plans a de novo filing with the FDA; Fromm appointed CEO.1 source
Adam Sachs becomes president of Vicarious Surgical; Bill Gates is listed among its investors.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Coverage
Newest first; wire copies grouped- Medical Device NetworkVicarious Surgical delays robot clinical timeline Vicarious Surgical has delayed the clinical timeline for its surgical robot, having previously stated it would initiate first-in-human clinical trial
- MedTech DiveVicarious Surgical delays robot timeline This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Vicarious Surgi
- GuruFocus.comVicarious Surgical Inc (RBOT) Q2 2025 Earnings Call Highlights: Strategic Delays and Cost Reductions Total Operating Expenses: $13.5 million, a 24% decrease from $17.7 million in Q2 2024. Research an
- MedTech DiveVicarious Surgical names Stephen From as next CEO This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: S